Ajax Therapeutics, a biopharmaceutical company focused on developing advanced JAK inhibitors for myeloproliferative neoplasms (MPNs), will present data from...

Rallybio Corporation announced positive findings from new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous...

PIF Partners’ investigational therapeutic, 101-PGC-005 (‘005), has received Rare Pediatric Disease Designation (RPDD) from the FDA for treating systemic...

Daiichi Sankyo will present over 45 abstracts showcasing new clinical research in various cancers at the 2024 ESMO Asia...

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved delgocitinib cream, a topical Janus kinase (JAK) inhibitor,...

TRIO Pharmaceuticals, a biotechnology company developing bispecific antibodies for cancer treatment, secured $3.1 million in pre-Series A funding. This...

Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a novel cancer drug resistance...

A secondary analysis of the IDEAL phase 3 randomized clinical trial, published in JAMA Network Open, confirms that the...

Janux Therapeutics, a clinical-stage biopharmaceutical company, announced positive interim clinical data for its JANX007 program, a Tumor Activated T...

Ajax Therapeutics announced the presentation of its ongoing first-in-human study of AJ1-11095, a next-generation Type II JAK2 inhibitor, at...